Literature DB >> 3429376

The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis.

G W Kaatz1, S L Barriere, D R Schaberg, R Fekety.   

Abstract

The efficacy of ciprofloxacin was compared with that of vancomycin in the rabbit model of methicillin-susceptible Staphylococcus aureus endocarditis. Animals were treated with ciprofloxacin, 25 mg/kg iv every 8 h or vancomycin, 17.5 mg/kg iv every 6 h, for 3, 6, or 9 days. Both drugs were found to be equally effective in the therapy of this infection, but the degree of reduction in bacterial counts was less than expected on the basis of previous studies. Additionally, resistance to ciprofloxacin in the test strain of S. aureus was seen to emerge in 12.5% of animals that received the drug. This raises concern about the use of ciprofloxacin as a single agent in the therapy of humans with serious systemic S. aureus infections.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3429376     DOI: 10.1093/jac/20.5.753

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  28 in total

1.  Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Brian T Tsuji; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

2.  Effect of promoter region mutations and mgrA overexpression on transcription of norA, which encodes a Staphylococcus aureus multidrug efflux transporter.

Authors:  Glenn W Kaatz; Rama V Thyagarajan; Susan M Seo
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Activity of new quinolones against ciprofloxacin-resistant staphylococci.

Authors:  G J Forstall; C C Knapp; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

4.  Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.

Authors:  J M Entenza; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 5.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

6.  Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus.

Authors:  T Takenouchi; F Tabata; Y Iwata; H Hanzawa; M Sugawara; S Ohya
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

7.  Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; S L Barriere; L M Albrecht; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

8.  Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.

Authors:  S M Palmer; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.

Authors:  S L Kang; M J Rybak; B J McGrath; G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

Review 10.  Lomefloxacin clinical pharmacokinetics.

Authors:  C D Freeman; D P Nicolau; P P Belliveau; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.